胃肠道神经内分泌肿瘤的消融磁共振引导放射治疗：评估局部控制与毒性
Ablative magnetic resonance-guided radiation for gastrointestinal neuroendocrine tumors: assessing local control and toxicity.
摘要(中文译文)
胃肠胰神经内分泌肿瘤（GEP-NETs）是神经内分泌肿瘤中一类惰性亚型，具有转移倾向。对于寡进展的患者，可考虑局部区域治疗，但并非适用于所有患者。立体定向体部放疗，包括磁共振引导放疗（MRgRT），已成为优化局部控制并减轻毒性的可选方案。本研究旨在评估MRgRT治疗GEP-NETs患者的疗效与安全性，重点关注局部控制和治疗相关毒性。研究对2019年至2023年间诊断为腹部神经内分泌肿瘤并接受MRgRT治疗的25例患者进行了回顾性分析。在排除神经内分泌癌及其他不符合条件的患者后，最终纳入20例高分化GEP-NETs患者进行分析。主要终点为局部控制和放射毒性；次要终点为自MRgRT之日起计算的无进展生存期和总生存期。研究队列的中位随访时间为44.5个月。MRgRT耐受性良好，仅2例（10%）患者出现急性3级治疗相关毒性。95%的患者实现了局部控制，中位无进展生存期为30个月。单因素分析中未发现与无进展生存期或毒性显著相关的变量。磁共振引导放疗是一种耐受性良好的治疗方法，可为GEP-NETs患者（包括转移性疾病患者）提供较高的局部控制率。对于不适合其他局部区域治疗的患者，该治疗应被视为一种可行的替代选择。
Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are an indolent subset of neuroendocrine neoplasms with a propensity to metastasize. In the case of oligoprogression, locoregional therapies are considered but may not be suitable for all patients. Stereotactic body radiotherapy, including magnetic resonance-guided radiotherapy (MRgRT), has emerged as an option to optimize local control and mitigate toxicity. This study aims to evaluate the efficacy and safety of MRgRT for treating patients with GEP-NETs, focusing on local control and treatment-related toxicity. A retrospective review was conducted on 25 patients diagnosed with abdominal neuroendocrine neoplasms and treated with MRgRT from 2019 to 2023. After excluding patients with neuroendocrine carcinomas and other noneligible conditions, 20 patients with well-differentiated GEP-NETs were included in the final analysis. Primary endpoints were local control and radiation toxicity; secondary endpoints were progression-free survival and overall survival calculated from the date of MRgRT. The study cohort had a median follow-up of 44.5 months. MRgRT was well-tolerated, with only two (10%) patients experiencing acute grade 3 treatment-related toxicity. Local control was achieved among 95% of patients, with a median progression-free survival of 30 months. No significant variables were associated with progression-free survival or toxicity in the univariate analysis. Magnetic resonance-guided radiotherapy is a well-tolerated treatment that offers high rates of local control for patients with GEP-NETs, including those with metastatic disease. This treatment should be considered a viable alternative for patients who are not candidates for other locoregional therapies.
如何引用
AMA
John S Peterson, Sarah Goodchild, Samyak Jain, John Michael Bryant, Mintallah Haider, Jonathan Strosberg, et al. Ablative magnetic resonance-guided radiation for gastrointestinal neuroendocrine tumors: assessing local control and toxicity.. Clinical and translational radiation oncology. 2027; doi:10.1016/j.ctro.2026.101286.
APA
John S Peterson, Sarah Goodchild, Samyak Jain, John Michael Bryant, Mintallah Haider, Jonathan Strosberg, et al (2027). Ablative magnetic resonance-guided radiation for gastrointestinal neuroendocrine tumors: assessing local control and toxicity.. Clinical and translational radiation oncology. https://doi.org/10.1016/j.ctro.2026.101286
GB/T 7714
John S Peterson, Sarah Goodchild, Samyak Jain, John Michael Bryant, Mintallah Haider, Jonathan Strosberg, et al. Ablative magnetic resonance-guided radiation for gastrointestinal neuroendocrine tumors: assessing local control and toxicity.[J]. Clinical and translational radiation oncology, 2027 doi:10.1016/j.ctro.2026.101286.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出